China Grand Pharmaceutical and Healthcare Holdings Limited announced that The board of the directors, based on the information currently available to the Company and the preliminary review by the management of the Company over the unaudited management accounts of the Group for the six months ended 30 June 2017, it is expected that the unaudited consolidated net profit attributable to owners of the Company recorded an increase of not less than 50% as compared to that of the six months ended 30 June 2016 (the unaudited consolidated net profit attributable to owners of the Company for the six months ended 30 June 2016 amounted to approximately HKD 110,831,000). The Board believes that the reason for the significant increment is mainly attributable to (among other things) the mid-to-long term development strategy of the Group has steadily contributed significant returns, and the product categories of the core products are enlarged through internal research and development and also merge and acquisition.